A Phase 3 open-label, randomized, multicenter study of NKTR-102 versus treatment of physician’s choice (TPC) in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine (ATTAIN)

• Any gender

• Single-agent cytotoxic chemotherapy indicated

• Can be measurable or non-measurable disease

• Must have a history of brain metastases that are non-progressing

• In TNBC, must have at least 1 prior lines of metastatic cytotoxic therapy

• In non-TNBC, prior therapy as indicated is required

• Have received prior therapy with anthracycline, taxane, and capecitabine in any setting (neo-adj, adj, or metastatic)

• Most recent anti-cancer therapy within 6 months of randomization

• ECOG PS 0-1

• No prior SCT

• No prior camptothecin-derived agent

• No leptomeningeal disease

• No HBV/HCV/HIV

• No cirrhosis

• No other malignancy within 5 years

• No need for O2 supplementation

OS; Secondary- PFS, PFS in brain, ORR, CBR, DoR, Safety